OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Pacheco on Frontline Therapy for Patients With EGFR-Mutant NSCLC

September 29th 2018

Jose M. Pacheco, MD, an assistant professor of medicine/medical oncology at the Colorado University School of Medicine, discusses frontline therapy for patients with EGFR-mutant non–small cell lung cancer (NSCLC).

Dr. Coleman on the Future of PARP Inhibitors in Ovarian Cancer

September 29th 2018

Robert L. Coleman, MD, FACOG, FACS, professor, Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, discusses the future of PARP inhibitors in patients with ovarian cancer.

Dr. Postow on FDA Approval of Cemiplimab in Metastatic Cutaneous Squamous Cell Carcinoma

September 29th 2018

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of cemiplimab in patients with advanced or metastatic cutaneous squamous cell carcinoma.

Dr. Rischin on the FDA Approval of Cemiplimab for CSCC

September 29th 2018

Danny Rischin, MD, director, Division of Cancer Medicine, head, Department of Medical Oncology, Peter MacCallum Cancer Centre, discusses the FDA approval of cemiplimab for the treatment of patients with cutaneous squamous cell carcinoma.

Dr. Cheng on the Need For Biomarkers in HCC

September 28th 2018

Ann-Lii Cheng, MD, distinguished professor, Department of Internal Medicine, National Taiwan University College of Medicine Director, Graduate Institute of Oncology, director, Department of Medical Oncology, discusses the need for biomarkers in hepatocellular carcinoma.

Dr. Bauml on Treatment For Oligometastatic NSCLC

September 28th 2018

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the treatment of patients with oligometastatic non–small cell lung cancer.

Dr. Kris on the FDA Approval of Dacomitinib in EGFR+ NSCLC

September 28th 2018

Mark G. Kris, MD, medical oncologist, William and Joy Ruane Chair in Thoracic Oncology, Memorial Sloan Kettering Cancer Center, discusses the FDA approval of dacomitinib for the frontline treatment of patients with EGFR-positive locally advanced or metastatic non–small cell lung cancer.

Dr. Basu on Second-Line Therapy in HCC

September 28th 2018

Bristi Basu, MD, honorary consultant medical oncologist, University of Cambridge, discussed second-line therapy for patients with hepatocellular carcinoma.

Dr. Sweis on the Frequency of Immune-Related Adverse Events in Kidney Cancer

September 28th 2018

Randy F. Sweis, MD, instructor of medicine, University of Chicago Medicine, discusses the frequency of immune-related adverse events (irAEs).

Dr. Deol on the Safety of CAR T-Cell Therapy

September 28th 2018

Abhinav Deol, MD, associate professor with Karmanos Cancer Institute, discusses patient eligibility for chimeric antigen receptor (CAR) T-cell therapy in hematologic oncology.

Dr. Radich on Treatment Discontinuation in CML Off Trial

September 28th 2018

Jerald P. Radich, MD, clinical research division, Fred Hutchinson Cancer Research Center, discusses treatment discontinuation off trial for patients with chronic myeloid leukemia (CML).

Dr. Gandara on Online Treatment Decision Tool for Lung Cancer

September 27th 2018

David R. Gandara, MD, director, Thoracic Oncology Program, professor, senior advisor to director, UC Davis Comprehensive Cancer Center, treasurer, International Association for the Study of Lung Cancer (IASLC), a 2017 Giant of Cancer Care® in Lung Cancer, discusses the idea for an online treatment decision tool for lung cancer.

Dr. Paulson Discusses Unmet Needs in the Treatment of NETs

September 27th 2018

Scott Paulson, MD, co-director of the Gastrointestinal Research Program for The US Oncology Network, medical director for the Neuroendocrine Research and Treatment Center at Baylor Charles A. Sammons Cancer Center, Baylor University Medical Center, discusses unmet needs in the treatment of patients with neuroendocrine tumors.

Dr. Smith Discusses Novel CAR T-Cell Therapies for Myeloma

September 27th 2018

Eric Smith, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses novel chimeric antigen receptor (CAR) T-cell therapies in development for the treatment of patients with multiple myeloma.

Dr. Tolaney on Recent Advances in HR-Positive Breast Cancer

September 27th 2018

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses recent advances in the treatment of patients with hormone receptor-positive breast cancer.

Dr. Wang on Managing AEs Related to BTK Inhibitors

September 27th 2018

Michael Wang, MD, professor in the Department of Lymphoma and Myeloma at The University of Texas MD Anderson Cancer Center, discusses how to manage adverse events related to BTK inhibitors in the treatment of mantle cell lymphoma.

Dr. Michaelis Discusses the JAK2 Mutation in MPNs

September 26th 2018

Laura Michaelis, MD, associate professor of medicine, Medical College of Wisconsin, discusses implications for the JAK2 mutation in patients with myeloproliferative neoplasms.

Dr. Heifetz Discusses Rural Oncology Care

September 26th 2018

Laurence J. Heifetz, MD, medical director, Gene Upshaw Memorial Tahoe Forest Cancer Center, discusses rural oncology care.

Dr. Llovet on Combination Therapy in HCC

September 26th 2018

Josep M. Llovet, MD, PhD, founder and director of the Liver Cancer Program, full professor of medicine, Icahn School of Medicine, Mount Sinai Hospital, discusses the potential of combination therapy in hepatocellular carcinoma.

Dr. Yang on the Future of Acute Myeloid Leukemia

September 26th 2018

Jay Yang, MD, oncologist, Barbara Ann Karmanos Cancer Institute, discusses the future of acute myeloid leukemia (AML).